Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial

Affiliations

¹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
² Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Electronic address: Stephanie_Dougan@dfci.harvard.edu.

Editorial

Max Heckler et al. Gastroenterology. 2018 Jul.

. 2018 Jul;155(1):11-14.

doi: 10.1053/j.gastro.2018.06.023. Epub 2018 Jun 6.

¹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
² Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Electronic address: Stephanie_Dougan@dfci.harvard.edu.

No abstract available

Comment on

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH. Beatty GL, et al. Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20. Gastroenterology. 2018. PMID: 29567081 Free PMC article. Clinical Trial.